Releasing the India BioEconomy Report at the three-days Global Bio-India (GBI) 2024 event on September 12 in New Delhi, Dr Rajesh Gokhale, Secretary, Department of Biotechnology (DBT) said“With more than five sectors generating over $1 billion each month, India’s BioEconomy reached a value of $151 billion in 2023. This growth is matched by a thriving entrepreneurial landscape, with 1,776 new biotech startups joining the ecosystem, showcasing India’s robust innovation capabilities”.
The report highlights the sector’s increasing significance as it now accounts for 4.25 per cent of India’s Gross Domestic Product (GDP) of $3.55 trillion in 2023. India’s BioEconomy registered a 10 per cent growth rate in 2023, characterised by a strong industrial focus, with BioIndustrial and BioPharma collectively accounting for over 83 per cent of the sector’s value.
Indian startups have developed over 800 products and raised more than $600 million in follow-on funding, as per the report. However, while 2022 saw 31 deals totalling $938.8 million, 2023 saw a dip, with only 16 deals worth $199.6 million. On a positive note, the medtech sector witnessed a robust growth in Foreign Direct Investment (FDI), rising from $370 million in 2022 to $480 million in 2023. In contrast, FDI in pharmaceuticals dropped from $2 billion to $1 billion in the same period, signalling shifting investment priorities.
This story is from the BioSpectrum India Oct 2024 edition of Bio Spectrum.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the BioSpectrum India Oct 2024 edition of Bio Spectrum.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber? Sign In
Agilent releases nextgen HPLC systems with enhanced automation and sustainability capabilities
Agilent Technologies Inc. has announced the release of its next generation Agilent InfinityLab LC Series portfolio, which includes the 1290 Infinity III LC, 1260 Infinity III Prime LC, and 1260 Infinity III LC systems, all including the biocompatible versions.
Univercells Technologies launches miniaturised scale-X Nexo Bioreactor
Univercells Technologies has announced the launch of its latest innovation, the scale-X nexo bioreactor.
Thermo Fisher and Telangana to establish Bioprocess Design Centre for novel biotherapeutics
Thermo Fisher Scientific has announced the signing of a Memorandum of Understanding (MoU) with the Government of Telangana to establish a Bioprocess Design Centre (BDC) in Genome Valley, Hyderabad.
VFL Sciences announces launch of GreatFlo Parallel Bioreactors and Fermentors
Chennai-based VFL Sciences has announced the launch of GreatFlo Parallel, a range of seamlessly parallel Bioreactors and Fermentors at the IKMC 2024 event organised by IKP Knowledge Park at Hyderabad recently, by Dr Jitendra Kumar, Managing Director, BIRAC.
Avantor opens new innovation centre for solving life science's biggest challenges
Avantor, Inc., a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, has announced the opening of its new flagship Bridgewater Innovation Centre.
Waters unveils new software to deliver lab-centric business intelligence
Waters Corporation has announced the launch of waters connect Data Intelligence software, a new cloud-based application that helps customers in regulated industries improve how they access, organise, analyse, and drive productivity from laboratory information.
INST develops unique drug delivery method to improve treatment of brain TB
Researchers at the Institute of Nano Science and Technology (INST), Mohali, have created a unique way to deliver Tuberculosis (TB) medicines directly to the brain bypassing the challenging blood-brain barrier (BBB) that limits the effectiveness of many brain TB medicines.
New way to create hydrogels from viral protein fragments for improving drug delivery
Researchers from Bose Institute, an autonomous institute of the Department of Science and Technology (DST), in Kolkata, have discovered a new way to create hydrogels using tiny protein fragments of just five amino acids from the SARS-CoV-1 virus, that could help improve targeted drug delivery & reduce side effects.
Lupin appoints Claus Jepsen as President, Global Specialty
Global pharma major Lupin has announced the appointment of Claus Jepsen as President, Global Specialty.
Shyamakant Giri to join as CEO of Gland Pharma
Gland Pharma’s Board has approved the appointment of Shyamakant Giri, as the new Chief Executive Officer (CEO) of the company.
